Detailed FundamentalsSingle-page fundamentals layout — broad valuation, growth, profitability, health, competitors, top funds & analyst detail.
Price chartUnavailable
Loading price history...
52-Week Range
Trailing twelve months
$312.53$483.99
1-Month Range
Month up 12.1%
$412.84$478.48
Daily Price Range
Day down -0.5%
$459.14$463.78
Volume
vs 3M avg
6616303M avg
Profile
Identity and capital structure
SectorUnclassified
IndustryCommon Stock
Market Cap$250.5B
Short % of Float—
Employees—
Sales$36,751M
Shares Outstanding540,911,490
IPO Date—
Last Reported Qtr.—
Next Qtr. Report—
Headquarters—
Homepagewww.amgn.com
Amgen Inc — Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients wi….· via yahoo
Warnings
1 signal
Live
- Debt/Equity elevated at 376.3
Scores
0–100 · higher is better except where noted · Insider Sent: directional buy ratio (excl. gifts/grants)
Value
65
Growth
83
Quality
95
Sentiment
95
Insider Sent.
0
Piotroski F
8
Altman Z
2.2
Consensus rating unavailable — no analyst coverage on file for AMGN.
Price targets unavailable — no 12-month targets on file for AMGN.
Valuation Engine
DCF Intrinsic Valuation Model
Run an interactive 5-year Discounted Cash Flow valuation on AMGN, calculate Margin of Safety, and stress-test WACC discount hurdles.
RetrievedQuote: Live · Insiders: Live · Fundamentals/Benchmarks: Curated · Vantage Composite · 1 warnings surfacedNov 11, 2026, 6:08 PM UTC